Targeting USP9X-AMPK axis in ARID1A-deficient hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "Cellular and molecular gastroenterology and hepatology"
DOI: 10.1016/j.jcmgh.2022.03.009
Abstract: BACKGROUND & AIMS Hepatocellular carcinoma(HCC) is a highly heterogeneous solid tumor with high morbidity and mortality. AT-Rich Interaction Domain 1A (ARID1A) accounts for up to 10% of mutations in liver cancer, however, its role in… read more here.
Keywords: hepatocellular carcinoma; hcc; targeting usp9x; usp9x ampk ... See more keywords